297 related articles for article (PubMed ID: 31858853)
1. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs.
Dignass A; Waller J; Cappelleri JC; Modesto I; Kisser A; Dietz L; DiBonaventura M; Wood R; May M; Libutzki B; Bargo D
J Med Econ; 2020 Apr; 23(4):415-427. PubMed ID: 31858853
[No Abstract] [Full Text] [Related]
2. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States.
Long MD; Smith TW; Dibonaventura M; Gruben D; Bargo D; Salese L; Quirk D
Inflamm Bowel Dis; 2020 May; 26(6):941-948. PubMed ID: 31560046
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis.
Long MD; Cohen RD; Smith TW; DiBonaventura M; Gruben D; Bargo D; Salese L; Quirk D
Dig Dis; 2022; 40(5):553-564. PubMed ID: 34879378
[TBL] [Abstract][Full Text] [Related]
4. Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis.
Brookes MJ; Waller J; Cappelleri JC; Modesto I; DiBonaventura MD; Bohm N; Mokgokong R; Massey O; Wood R; Bargo D
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32938582
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis.
Cichewicz A; Tencer T; Gupte-Singh K; Egodage S; Burnett H; Kumar J
Adv Ther; 2023 May; 40(5):2116-2146. PubMed ID: 37000363
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis.
Stewart MJ; Bessissow T; Gregor J; Hazel M; In TSH; Karra K; Dajnowiec D; Williamson M; Sattin B
Adv Ther; 2021 Jul; 38(7):4115-4129. PubMed ID: 34159558
[TBL] [Abstract][Full Text] [Related]
7. Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use.
Bargo D; Tritton T; Cappelleri JC; DiBonaventura M; Smith TW; Tsuchiya T; Gardiner S; Modesto I; Holbrook T; Bluff D; Kobayashi T
Inflamm Intest Dis; 2021 Dec; 6(4):186-198. PubMed ID: 35083284
[TBL] [Abstract][Full Text] [Related]
8. Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany.
Pöllinger B; Schmidt W; Seiffert A; Imhoff H; Emmert M
Eur J Health Econ; 2019 Mar; 20(2):195-203. PubMed ID: 29362899
[TBL] [Abstract][Full Text] [Related]
9. Inadequate Response, Treatment Patterns, Health Care Utilization, and Associated Costs in Patients With Ulcerative Colitis: Retrospective Cohort Study Based on German Claims Data.
Bokemeyer B; Picker N; Wilke T; Rosin L; Patel H
Inflamm Bowel Dis; 2022 Nov; 28(11):1647-1657. PubMed ID: 35134912
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
[TBL] [Abstract][Full Text] [Related]
11. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
[TBL] [Abstract][Full Text] [Related]
12. Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases.
Sah J; Teeple A; Muser E; Gutierrez C; Dassopoulos T
Curr Med Res Opin; 2022 Jul; 38(7):1093-1101. PubMed ID: 35475385
[TBL] [Abstract][Full Text] [Related]
13. Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease.
Ehrenberg R; Griffith J; Theigs C; McDonald B
J Manag Care Spec Pharm; 2020 Jun; 26(6):758-765. PubMed ID: 32191593
[TBL] [Abstract][Full Text] [Related]
14. The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom.
Lindsay JO; Picker N; Kromer D; Smyth M; Patel H
Curr Med Res Opin; 2023 May; 39(5):681-689. PubMed ID: 36951899
[TBL] [Abstract][Full Text] [Related]
15. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
Chen KC; Wu CH; Tang CH; Huang KC
PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
[TBL] [Abstract][Full Text] [Related]
17. Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data.
Black CM; Yu E; McCann E; Kachroo S
PLoS One; 2016; 11(2):e0149692. PubMed ID: 26919745
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease.
Perera S; Yang S; Stott-Miller M; Brady J
J Health Econ Outcomes Res; 2018; 6(1):96-112. PubMed ID: 32685575
[TBL] [Abstract][Full Text] [Related]
19. Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting.
Bokemeyer B; Ghiani M; Fuchs A; Deiters B; Hardtstock F; Brandes A; Knop J; Orzechowski HD; Wilke T
Int J Colorectal Dis; 2020 Aug; 35(8):1587-1598. PubMed ID: 32424526
[TBL] [Abstract][Full Text] [Related]
20. Real-World Prescription Pattern and Healthcare Cost Among Patients with Ulcerative Colitis in Japan: A Retrospective Claims Data Analysis.
Miyazaki C; Sakashita T; Jung W; Kato S
Adv Ther; 2021 May; 38(5):2229-2247. PubMed ID: 33515423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
